OOIR: Observatory of International Research

Papers

(The TQCC of Medicinal Research Reviews is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications	320
Molecular targeting therapies for neuroblastoma: Progress and challenges	177
The role of hypoxia‐inducible factor 1 in tumor immune evasion	173
Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions	164
Understanding the tumor microenvironment for effective immunotherapy	164
Mechanisms of melanocyte death in vitiligo	136
A review in radiomics: Making personalized medicine a reality via routine imaging	128
Tripterygium wilfordii: An inspiring resource for rheumatoid arthritis treatment	120
Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections	105
Phytochemistry and cardiovascular protective effects of Huang‐Qi (Astragali Radix)	98
The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases	94
Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation	88
Emerging roles of SIRT6 in human diseases and its modulators	86
What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design	85
Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments	75
Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases	75
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy	71
KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential	70
Direct targeting of β‐catenin in the Wnt signaling pathway: Current progress and perspectives	68
Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review	66
Mechanism of epithelial‐mesenchymal transition in cancer and its regulation by natural compounds	63
Extracellular vesicles: Emerging frontiers in wound healing	63
Strategies for designing proteolysis targeting chimaeras (PROTACs)	59
Expedition of sulfur‐containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update	53
Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease	52

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy	52
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition	51
Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets	50
Cardiac efficacy and toxicity of aconitine: A new frontier for the ancient poison	50
Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment	48
Cistanches Herba, from an endangered species to a big brand of Chinese medicine	48
Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone‐methide triterpenoid celastrol	46
Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness	46
Inflammatory bowel disease biomarkers	45
The Yin and Yang of traditional Chinese and Western medicine	44
Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and disease networks: A comprehensive approach	44
Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles	42
Progress and perspective on hydrogen sulfide donors and their biomedical applications	42
Recent progress and new perspectives for diterpenoid biosynthesis in medicinal plants	41
Salinomycin as a potent anticancer stem cell agent: State of the art and future directions	40
SARS‐CoV‐2‐mediated immune system activation and potential application in immunotherapy	39
Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer	38
Pipeline of anti‐Mycobacterium abscessussmall molecules: Repurposable drugs and promising novel chemical entities	38
Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response	37
Drug design targeting active posttranslational modification protein isoforms	37
Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors	37
Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling	36
The role of Wnt signaling in skin fibrosis	35
Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment	32
Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives	31
Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin	30
The role of long noncoding RNA in lipid, cholesterol, and glucose metabolism and treatment of obesity syndrome	30
Antioxidant peptides, the guardian of life from oxidative stress	30
Adipose‐derived stromal cells for nonhealing wounds: Emerging opportunities and challenges	30
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications	30
The antiviral and immunomodulatory activities of propolis: An update and future perspectives for respiratory diseases	29
Artemisinin inspired synthetic endoperoxide drug candidates: Design, synthesis, and mechanism of action studies	29
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets	29
Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective	28
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma	28
Recent pharmacological advances in the repurposing of artemisinin drugs	28
ER stress and inflammation crosstalk in obesity	27
Druggability modification strategies of the diarylpyrimidine‐type non‐nucleoside reverse transcriptase inhibitors	27
A potential therapeutic strategy for prostatic disease by targeting the oral microbiome	27
Microglia‐derived galectin‐3 in neuroinflammation; a bittersweet ligand?	27
Combining stem cells in myocardial infarction: The road to superior repair?	27
Incomplete autophagy: Trouble is a friend	26
Lipidomic landscape in cancer: Actionable insights for membrane‐based therapy and diagnoses	26
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline	26
Discovery of K_V1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges	25
The antigen‐binding moiety in the driver's seat of CARs	25
Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics	24
Artemisinin‐derived dimers from a chemical perspective	24
Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors	24
Nanotechnology‐based electrochemical biosensors for monitoring breast cancer biomarkers	23

Recent progresses and remaining challenges for the detection of Zika virus	23
Ribosome‐targeting antibacterial agents: Advances, challenges, and opportunities	23
1,3‐Diazepine: A privileged scaffold in medicinal chemistry	23
Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment	23
The lymphatic vasculature: An active and dynamic player in cancer progression	23
Mitochondrial quality control proteases and their modulation for cancer therapy	23
Epigenetic modifications in pancreas development, diabetes, and therapeutics	22
Small molecules as modulators of regulated cell death against ischemia/reperfusion injury	22
Targeted nanomedicines for the treatment of bone disease and regeneration	21
Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery	20
Bacterial proton motive force as an unprecedented target to control antimicrobial resistance	20
Emerging insights on the role of V‐ATPase in human diseases: Therapeutic challenges and opportunities	20